Zontivity (vorapaxar tablets) — Cigna

reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD)

Initial criteria

Patient has a previous myocardial infarction (MI) or peripheral arterial disease (PAD); AND
Patient weighs ≥ 60 kg; AND
Patient is receiving Zontivity in combination with aspirin and/or clopidogrel; AND
Patient has been determined by the prescriber to be at high risk for future thrombotic events (examples of high risk include multiple myocardial infarctions, multiple urgent coronary revascularization procedures, coronary artery stent placement, or other concomitant diseases that increase cardiovascular risk such as diabetes)

1 year